Creative Biostructure develops a safe, effective and straightforward strategy to rapidly produce a Zika vaccine. Our Zika Virus VLPs are composed of partially mature particles containing Envelope (E), pre-Membrane (prM) and Membrane (M). VLPs are produced in mammalian suspension cell cultures offering a suitable system for rapid scale up of manufacturing, without the risk of working with an infectious agent. The lack of infectivity of the product eliminates the need for chemical inactivation, which may compromise vaccine efficacy and safety. The particulate nature of the vaccine and the preservation of a variety of conformational antigenic sites may even render this vaccine efficacious in humans without using adjuvant if its incorporation into a vaccine raises safety concerns. In summary, the Zika VLP platform puts forward a vaccine composition and production system ready for clinical development of a safe and effective prophylactic Zika vaccine, which is greatly needed to meet the challenges imposed by the spread of the Zika epidemic.
Zika virus is an emerging disease that is spread by Aedes mosquitoes. The virus was first isolated in Central Africa, and has since spread to South Asia and more recently to South America. It is a member of the flavivirus family, and is structurally closely related to viruses such as Dengue Fever Virus. Outbreaks were reported in Micronesia in 2007 and in Brazil in 2015, confirming at least 13 autochthonous infections. The Zika virus outbreak in Brazil in 2016 has gained world-wide attention, and has been linked to an increasing number of microcephaly cases. In April 2016 the Centers for Disease Control, in the USA, confirmed the link between Zika virus infection of the fetus with microcephaly.
Clinically Zika virus can cause mild fever, rash, myalgia, arthralgia and headaches, with one in four infected individuals being asymptomatic. Due to similar symptoms Zika virus infected individuals can easily be mis-diagnosed as a dengue infection and vice-versa. In addition, Zika virus has been implicated in causing microcephaly through transmission in utero. There is no vaccine or specific treatment available for Zika virus.
Analysis of Zika virus sequences from infected patients have shown that the strain circulating in South America in 2015 is most closely related to the strains circulating in Asia during outbreaks in 2007 and 2013-14. The South American strain was first isolated and sequenced from a patient in Suriname, and hence is known as the Zika Suriname strain.
We provide highly purified Virus-Like Particles (VLPs) products as antigens, produced in a native format, mostly using a mammalian expression system. Custom VLPs synthesis is also offered presented as a cell lysate or a purified antigen for use in vaccine development (including use as an immunogen) and serological based diagnostic assays. We like to be in touch with our customers so please feel free to contact us for a formal quote.